AU2003216111C1 - Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof - Google Patents
Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof Download PDFInfo
- Publication number
- AU2003216111C1 AU2003216111C1 AU2003216111A AU2003216111A AU2003216111C1 AU 2003216111 C1 AU2003216111 C1 AU 2003216111C1 AU 2003216111 A AU2003216111 A AU 2003216111A AU 2003216111 A AU2003216111 A AU 2003216111A AU 2003216111 C1 AU2003216111 C1 AU 2003216111C1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- astrocyte
- restricted precursor
- precursor cells
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004027 cell Anatomy 0.000 title claims description 219
- 239000002243 precursor Substances 0.000 title claims description 84
- 210000001130 astrocyte Anatomy 0.000 title claims description 81
- 238000000034 method Methods 0.000 title claims description 42
- 238000002955 isolation Methods 0.000 title description 5
- 102100032912 CD44 antigen Human genes 0.000 claims description 36
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 36
- 210000004248 oligodendroglia Anatomy 0.000 claims description 23
- 230000001537 neural effect Effects 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 210000003061 neural cell Anatomy 0.000 claims description 13
- 230000036573 scar formation Effects 0.000 claims description 13
- 239000007943 implant Substances 0.000 claims description 12
- 230000002518 glial effect Effects 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 210000003754 fetus Anatomy 0.000 claims description 6
- 230000023105 myelination Effects 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 description 28
- 210000002569 neuron Anatomy 0.000 description 16
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 14
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 14
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000006378 damage Effects 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 102100037362 Fibronectin Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- 102000008730 Nestin Human genes 0.000 description 6
- 108010088225 Nestin Proteins 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 210000005055 nestin Anatomy 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 108010085895 Laminin Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010061431 Glial scar Diseases 0.000 description 4
- 206010018341 Gliosis Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000002894 multi-fate stem cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101001123834 Homo sapiens Neprilysin Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000003140 astrocytic effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000005155 neural progenitor cell Anatomy 0.000 description 3
- 210000000276 neural tube Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 101150022753 galc gene Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710164125 Tubulin alpha-1 chain Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- -1 serum Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35103602P | 2002-01-23 | 2002-01-23 | |
| US60/351,036 | 2002-01-23 | ||
| PCT/US2003/002356 WO2003061392A1 (en) | 2002-01-23 | 2003-01-23 | Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2003216111A1 AU2003216111A1 (en) | 2003-09-18 |
| AU2003216111B2 AU2003216111B2 (en) | 2008-02-21 |
| AU2003216111C1 true AU2003216111C1 (en) | 2008-08-21 |
Family
ID=27613451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003216111A Ceased AU2003216111C1 (en) | 2002-01-23 | 2003-01-23 | Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20050214940A1 (enExample) |
| EP (1) | EP1476020A4 (enExample) |
| JP (2) | JP2006503543A (enExample) |
| KR (1) | KR20040075957A (enExample) |
| AU (1) | AU2003216111C1 (enExample) |
| CA (1) | CA2473749C (enExample) |
| NZ (1) | NZ534381A (enExample) |
| WO (1) | WO2003061392A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005517717A (ja) | 2002-02-15 | 2005-06-16 | コーネル リサーチ ファンデーション， インコーポレーティッド | 希突起膠細胞前駆細胞を用いた先天性髄鞘発育不全の前脳の有髄化 |
| EP2283116B1 (en) | 2008-05-08 | 2016-09-28 | University Of Rochester | Treating myelin diseases with optimized cell preparations |
| JP6541577B2 (ja) | 2013-02-06 | 2019-07-10 | ユニバーシティー オブ ロチェスター | ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞 |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| WO2017172976A1 (en) * | 2016-03-29 | 2017-10-05 | The Regents Of The University Of California | Methods for promoting oligodendrocyte regeneration and remyelination |
| WO2018209022A2 (en) | 2017-05-10 | 2018-11-15 | University Of Rochester | Methods of treating neuropsychiatric disorders |
| CN113337469B (zh) * | 2021-07-16 | 2023-03-24 | 广州市妇女儿童医疗中心 | 星形胶质细胞亚群及其分离纯化方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202120A (en) * | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
| US6204053B1 (en) * | 1994-11-08 | 2001-03-20 | Diacrin, Inc. | Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| US5874301A (en) * | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| US6235527B1 (en) * | 1997-11-29 | 2001-05-22 | University Of Utah Research Foundation | Lineage restricted glial precursors from the central nervous system |
| EP1248519A4 (en) * | 2000-01-18 | 2004-03-31 | Univ Leland Stanford Junior | EXPANSION OF STEM AND PROCUREMENT CELLS BY BETA-CATENIN |
| CA2409698C (en) * | 2000-05-17 | 2010-10-26 | Geron Corporation | Neural progenitor cell populations |
| US7560280B2 (en) * | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
-
2003
- 2003-01-23 KR KR10-2004-7011381A patent/KR20040075957A/ko not_active Ceased
- 2003-01-23 WO PCT/US2003/002356 patent/WO2003061392A1/en not_active Ceased
- 2003-01-23 EP EP03732101A patent/EP1476020A4/en not_active Withdrawn
- 2003-01-23 CA CA2473749A patent/CA2473749C/en not_active Expired - Fee Related
- 2003-01-23 AU AU2003216111A patent/AU2003216111C1/en not_active Ceased
- 2003-01-23 NZ NZ534381A patent/NZ534381A/en unknown
- 2003-01-23 JP JP2003561348A patent/JP2006503543A/ja active Pending
- 2003-01-23 US US10/502,224 patent/US20050214940A1/en not_active Abandoned
-
2008
- 2008-05-28 JP JP2008139534A patent/JP2008289486A/ja active Pending
-
2009
- 2009-04-30 US US12/433,060 patent/US8673292B2/en not_active Expired - Lifetime
-
2014
- 2014-03-10 US US14/202,121 patent/US20140186314A1/en not_active Abandoned
-
2015
- 2015-01-20 US US14/600,299 patent/US20150152382A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150152382A1 (en) | 2015-06-04 |
| US20140186314A1 (en) | 2014-07-03 |
| NZ534381A (en) | 2008-04-30 |
| US20050214940A1 (en) | 2005-09-29 |
| JP2008289486A (ja) | 2008-12-04 |
| WO2003061392A1 (en) | 2003-07-31 |
| EP1476020A4 (en) | 2006-01-11 |
| CA2473749A1 (en) | 2003-07-31 |
| US20090220567A1 (en) | 2009-09-03 |
| EP1476020A1 (en) | 2004-11-17 |
| KR20040075957A (ko) | 2004-08-30 |
| AU2003216111B2 (en) | 2008-02-21 |
| CA2473749C (en) | 2012-05-22 |
| US8673292B2 (en) | 2014-03-18 |
| JP2006503543A (ja) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Svendsen et al. | Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease | |
| Sonigra et al. | Adult rat olfactory nerve ensheathing cells are effective promoters of adult central nervous system neurite outgrowth in coculture | |
| US7795021B2 (en) | Lineage restricted glial precursors from the central nervous system | |
| US9795637B1 (en) | Human cord blood as a source of neural tissue repair of the brain and spinal cord | |
| JP5649745B2 (ja) | インビトロでオリゴデンドロサイト系列細胞に分化しやすい哺乳類神経幹細胞および／または神経前駆細胞の純粋または富化集団を入手および維持するための培養方法 | |
| US20150152382A1 (en) | Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof | |
| US20050003531A1 (en) | Lineage-restricted neuronal precursors | |
| JP2001526884A (ja) | 神経前駆細胞、その製造方法および神経性欠陥治療におけるその使用 | |
| US20020168767A1 (en) | Method of isolating human neuroepithelial precursor cells from human fetal tissue | |
| AU2003216111A1 (en) | Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof | |
| WO2013012269A2 (ko) | 전능성 줄기세포로부터 희소돌기아교 전구세포의 제조 방법 | |
| CN101679951B (zh) | 端脑胶质限制性细胞群和相关组合物及方法 | |
| JP3636474B2 (ja) | 正常神経上皮前駆細胞 | |
| Maier et al. | In vitro and in vivo characterization of blastemal cells from regenerating newt limbs | |
| Lepski | A comparative analysis of human adult mesenchymal and fetal neuronal stem cells with regard to their neurogenic potential: an electrophysiological and immuncytochemical analysis of the differentiation potential of human mesenchymal and human fetal neural stem cells towards a mature neuronal phenotype | |
| Richardson | Transplantation of adult subependymal zone neuronal progenitor cells to diverse environments of the adult brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-APPLICANT FROM THE GOVERNMENT OF THE UNITED STATES OF AMERICA TO THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES. |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2008. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2008 |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |